Q4 Drug Testing Compliance Check: 5 Things Employers Should Review Before Year-End
For many employers, workplace drug testing compliance is reviewed only when a test is challenged, an audit is announced, or a safety incident occurs. That approach creates avoidable risk. A program can appear operationally smooth while still containing gaps in policy language, collection procedures, laboratory coordination, or recordkeeping.
Q4 is the appropriate time to conduct a structured review. Employers should confirm that their drug testing program reflects current requirements, distinguishes DOT and non-DOT testing, and produces documentation that can be retrieved if a regulator, attorney, employee, or business partner asks for it.
Prime Diagnostic Testing supports employers as a Third-Party Administrator (TPA) and testing coordinator. Prime coordinates workplace drug testing among employers, collection sites, Medical Review Officers, and accredited or certified laboratories. Prime is not a laboratory, medical clinic, or walk-in collection facility.
Use the following five-point review before year-end.
1. Confirm that your written policy matches how testing actually occurs
The most common compliance gap is a difference between the written policy and the employer’s day-to-day practices. A policy may describe one testing panel, collection method, or notification process while managers and vendors follow another.
Review whether your policy clearly addresses:
Which employees and job classifications are covered
Whether positions are safety-sensitive
The circumstances that trigger testing, such as:
The specimen types and testing panels used
The handling of negative, positive, invalid, cancelled, adulterated, substituted, and refused tests
Employee notification, consent, and confidentiality procedures
The person responsible for receiving results and taking employment action
The process for addressing prescription medications, marijuana-related laws, and reasonable accommodations where applicable
Employers should also review state and local requirements. Rules affecting pre-employment testing, random testing, marijuana, privacy, and adverse employment decisions can vary by jurisdiction.
Consistency is central to defensibility. Similar employees should be subject to comparable testing rules unless there is a documented, lawful reason for different treatment. HR, legal, safety, and operations leaders should review the policy together so the document reflects actual business practices.
2. Separate DOT and non-DOT requirements
DOT and non-DOT testing are not interchangeable. Treating them as one program can create regulatory and legal exposure.
DOT-regulated employers must follow 49 CFR Part 40 along with the rules of the applicable DOT agency, such as FMCSA, FAA, FRA, FTA, PHMSA, or the U.S. Coast Guard. The U.S. Department of Transportation employer resources provide current agency information, random testing rates, forms, laboratory resources, and recordkeeping guidance.
Non-DOT testing is governed primarily by the employer’s written policy and applicable federal, state, and local law. It may use different forms, panels, procedures, and testing circumstances.
Your Q4 review should confirm that:
DOT-covered and non-DOT employees are identified separately
DOT testing uses the required Federal Custody and Control Form and applicable DOT forms
Non-DOT testing uses non-DOT forms and does not use DOT forms with agency references removed
DOT and non-DOT specimens are handled as separate testing events
DOT random pools exclude employees who are not covered by DOT regulations
DOT pre-employment, random, post-accident, reasonable suspicion, return-to-duty, and follow-up procedures are documented
FMCSA employers have reviewed applicable Clearinghouse requirements
Designated Employer Representative (DER) responsibilities are clearly assigned
Supervisors who may make reasonable-suspicion determinations have completed required training
Under Part 40, employers remain responsible for compliance even when they use a service agent or TPA. A TPA can coordinate processes, maintain records, and connect the employer with qualified providers, but it does not replace the employer’s responsibility for policy decisions and required employment actions.
Prime’s DOT drug testing coordination services and non-DOT testing services are designed around this distinction.
3. Audit collection and chain-of-custody procedures
A compliant test depends on more than the test panel. The collection process must preserve specimen identity, integrity, privacy, and traceability from the collection site to the laboratory.
Review your collection-site workflow for the following controls:
Positive identification of the employee
Correct test reason and specimen type
Use of properly trained collectors
Privacy and restricted access at the collection site
Inspection of the collection area when required
Accurate labeling of specimens
Tamper-evident seals
Completion of all required custody and control form fields
Secure specimen packaging and transportation
Documentation of each transfer of custody
Prompt escalation of refusals, insufficient specimens, temperature problems, suspected tampering, and other irregularities
For DOT testing, the Federal Custody and Control Form documents the chain of custody and must be completed according to Part 40. Employers should verify that collection sites have current forms, appropriate collection supplies, clear DER contact information, and a process for correcting errors.
For non-DOT testing, employers should establish a comparable chain-of-custody protocol even when a particular procedure is not expressly required by law. A defensible program should show who handled the specimen, when it was transferred, where it was stored, and how it reached the testing laboratory.
A broken or incomplete chain of custody can delay results, require recollection, undermine employee due process, and weaken the employer’s position in a dispute.
4. Verify laboratory certification, accreditation, and result review
Employers should know where specimens are tested and what qualifications apply to the laboratory.
For DOT drug testing, laboratories must meet the applicable HHS certification requirements under the National Laboratory Certification Program. The current HHS-certified laboratory resources should be used to verify laboratory eligibility.
For non-DOT programs, employers should confirm that the selected laboratory is appropriately accredited or certified for the testing performed and that it follows validated procedures for screening, confirmation, specimen validity testing, quality control, and secure reporting. Requirements can vary based on the test type, jurisdiction, and employer policy.
Your year-end review should address:
Which laboratory receives each type of specimen
Whether the laboratory is certified or accredited for the applicable testing
Whether non-negative screening results receive laboratory confirmation
Whether a qualified Medical Review Officer reviews results when appropriate
How invalid, adulterated, substituted, and cancelled results are reported
How employees are contacted for medical review when required
Whether result transmission is secure and limited to authorized recipients
Whether laboratory and MRO contact information is current
A laboratory result should not be treated as an automatic employment decision. The result must be interpreted under the applicable program, reviewed through the appropriate medical and regulatory process, and handled consistently with the employer’s policy.
Prime coordinates these administrative steps between employers, collection sites, Medical Review Officers, and partner laboratories. Prime does not perform laboratory analysis.
5. Reconcile records, reporting, and year-end documentation
A compliance program is difficult to defend when records are incomplete, scattered across email accounts, or retained without a defined schedule.
Before year-end, reconcile your records against the testing activity that occurred during the year. Include:
Current and prior versions of the drug testing policy
Employee notices and acknowledgments
Test authorizations and testing logs
Random selection records
Collection-site documentation
Custody and control forms
Laboratory reports
MRO determinations
Refusal and recollection documentation
Training records for DERs and supervisors
Clearinghouse records, when applicable
MIS reporting documentation, when applicable
Corrective actions and internal audit notes
DOT retention requirements vary by record type. Under 49 CFR § 40.333, certain positive results, refusals, SAP reports, and follow-up testing records generally require five-year retention. Previous-employer information generally requires three-year retention. Negative and cancelled drug test records generally require one-year retention. Employers should confirm the current requirements for their specific DOT agency and program.
Records should be stored securely with role-based access. Managers should not receive more medical information than they need to carry out their responsibilities. The employer should also be able to retrieve organized records promptly if an agency inspection, litigation matter, employee appeal, or client audit occurs.
A practical Q4 review sequence
Employers can complete the review in five steps:
Compare the written policy with actual testing practices.
Separate DOT and non-DOT workflows, forms, pools, and reporting.
Sample completed collections and verify chain-of-custody documentation.
Confirm laboratory and MRO qualifications and current contact information.
Reconcile records, retention schedules, training, and required reports.
Do not wait until a compliance issue forces the review. Small administrative errors are easier to correct before they affect a hiring decision, safety-sensitive assignment, audit, or legal proceeding.
Coordinate your year-end compliance review with Prime
A reliable workplace drug testing program requires coordination across multiple parties. Employers must manage policies, employees, supervisors, collection sites, laboratories, MROs, and records without losing control of the workflow.
Prime Diagnostic Testing serves as the administrative hub for employer testing programs. We help coordinate drug testing for employers, connect employees with appropriate collection sites, support DOT and non-DOT workflows, and manage communication through the testing process. Services are coordinated nationwide through a network of collection and laboratory partners.
To begin a Q4 review of your employer drug testing program, contact Prime Diagnostic Testing or call (470) 894-4866. A consultation can identify process gaps, clarify DOT versus non-DOT requirements, and establish a practical starting point for a more organized and defensible year-end compliance program.
Sources and regulatory references
Comments